查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1572298

β 地中海型贫血测试市场：按测试类型、最终用户、技术划分 - 2025-2030 年全球预测

Beta Thalassemia Testing Market by Test Type (Carrier Screening, Diagnostic Testing, Newborn Screening), End User (Diagnostic Laboratories, Hospitals, Research Institutes), Technology - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年β地中海贫血检测市值为4.4683亿美元，预计到2024年将达到4.7847亿美元，复合年增长率为8.37%，到2030年将达到7.8435亿美元。

β-地中海型贫血检测是遗传和产前检测市场的重要组成部分，因为它是一种遗传性疾病。这包括诊断β地中海贫血的基因筛检，这是一种以血红蛋白产生减少为特征的血液疾病。这项测试至关重要，特别是在该疾病高发生率中，例如地中海、中东和东南亚地区，因为它有助于早期诊断和更好地管理疾病。 β地中海型贫血检测的应用范围包括潜在基因携带者的产前检测、新生儿筛检以及有症状个体的明确诊断。最终用途主要是医院、诊断实验室和专科诊所。

主要市场统计
基准年[2023] 44683万美元
预测年份 [2024] 47847万美元
预测年份 [2030] 7.8435 亿美元
复合年增长率（%） 8.37%

β地中海贫血检测市场受到成长要素的影响，例如对遗传疾病认识的提高、次世代定序仪等基因检测技术的进步以及对促进遗传疾病筛检的医疗保健政策的支持。此外，持续的研发工作和策略联盟以开发更准确、更快速和更具成本效益的测试解决方案也带来了巨大的机会。例如，利用 CRISPR-Cas9 技术可以提高测试能力，并为有前景的业务扩展领域提供业务洞察。然而，新兴国家面临先进诊断测试的有限性和基因测试通讯协定的严格监管等挑战，影响了整体市场的成长潜力。

透过将人工智慧整合到自动化和资料分析中，在提高检测精度和降低成本方面存在大量创新机会。与研究机构合作开发综合基因组也可能增强市场地位。产业参与者应注重地理扩张，尤其是地中海贫血负担较高的开拓农村地区。市场竞争格局温和，主要受到技术进步和医疗保健支出成长的推动。能够在确保合规性和扩大测试范围的同时进行创新的公司将能够利用该行业的信誉和成长潜力。

市场动态：揭示快速发展的β地中海贫血测试市场的关键市场洞察

供需的动态交互作用正在改变β地中海贫血检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球β-地中海贫血的盛行率不断上升，增加了对专门检测方法的需求。
    • 提高人们对β-地中海贫血的早期发现和管理的认识并加强政府的努力
    • 扩大发展中地区的医疗基础设施，以提供β地中海贫血检测
  • 市场限制因素
    • 与先进诊断技术相关的先进测试技术高成本
  • 市场机会
    • 开发一种具有成本效益的检测方法，使β-地中海贫血筛检广泛应用
    • 提高公众意识和政府努力促进β地中海贫血检测和管理
    • 医疗保健提供者和生物技术公司之间的合作推进了β地中海贫血检测
  • 市场挑战
    • 在农村和人口稀少地区，使用专门医疗设施进行 β 地中海贫血检测的机会有限。

波特五力：驾驭β地中海贫血检测市场的策略工具

波特五力是了解β地中海贫血测试市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解β地中海贫血检测市场的外部影响

外部宏观环境因素在塑造β地中海贫血测试市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解β地中海贫血检测市场的竞争状况

对β地中海贫血测试市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 Beta 地中海贫血测试市场供应商的绩效评估

FPNV 定位矩阵是评估 Beta 地中海贫血测试市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘β地中海贫血检测市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，β 地中海贫血测试市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • β-地中海型贫血的盛行率在全球范围内不断增加，增加了对专门检测方法的需求。
      • 提高人们对β地中海贫血的早期发现和管理的认识并加强政府的努力
      • 扩大开发中地区的医疗基础设施允许进行β地中海贫血检测
    • 抑制因素
      • 与先进诊断技术相关的先进测试技术高成本
    • 机会
      • 开发具有成本效益的检测方法，以实现β-地中海贫血筛检的广泛应用
      • 政府努力提高公众意识并促进β地中海贫血检测和管理
      • 医疗保健提供者和生物技术公司之间的合作加速了β地中海贫血检测的进展
    • 任务
      • 在无法获得专门医疗保健设施的农村和发展中地区进行β地中海贫血检测
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章 按测试类型分類的β地中海贫血测试市场

  • 职业筛检
  • 诊断测试
    • 基因检测
    • 验血
  • 新生儿筛检
  • 产前检测
    • 侵入性产前检测
    • 非侵入性产前检测（NIPT）

第 7 章 β 地中海型贫血测试市场：依最终用户分类

  • 诊断实验室
  • 医院
  • 调查机构
  • 专科诊所

第 8 章 β 地中海型贫血检测市场：依技术分类

  • 微阵列技术
  • 次世代定序（NGS）
  • PCR（聚合酵素链锁反应）

第九章 美洲β地中海贫血检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区β地中海贫血检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲β地中海贫血检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-9A6A6F297442

The Beta Thalassemia Testing Market was valued at USD 446.83 million in 2023, expected to reach USD 478.47 million in 2024, and is projected to grow at a CAGR of 8.37%, to USD 784.35 million by 2030.

Beta Thalassemia testing is a critical segment within the genetic and prenatal testing market due to the hereditary nature of the disorder. It involves genetic screening to diagnose beta thalassemia, a blood disorder characterized by reduced hemoglobin production. This testing is essential in populations with a high prevalence of the disease, particularly in Mediterranean, Middle Eastern, and Southeast Asian regions, as it aids early diagnosis and better management of the disorder. Applications of beta thalassemia testing span prenatal testing for potential gene carriers, newborn screenings, and confirmatory diagnostics for symptomatic individuals. End-use scope majorly involves hospitals, diagnostic laboratories, and specialized clinics.

KEY MARKET STATISTICS
Base Year [2023] USD 446.83 million
Estimated Year [2024] USD 478.47 million
Forecast Year [2030] USD 784.35 million
CAGR (%) 8.37%

The market for beta thalassemia testing is influenced by growth factors such as increased awareness regarding genetic diseases, advancements in genetic testing technologies like next-gen sequencing, and supportive healthcare policies promoting genetic disorder screening. Moreover, ongoing research and development activities and strategic collaborations for developing more precise, faster, and cost-effective testing solutions present significant opportunities. For instance, leveraging CRISPR-Cas9 technology could enhance testing capabilities, offering business insights into promising areas for expansion. However, the market faces challenges like limited accessibility to advanced diagnostic tests in emerging economies and regulatory stringencies concerning genetic testing protocols, impacting overall growth potential.

Innovation opportunities abound in improving testing accuracy and reducing costs through automation and integration of AI in data analysis. Collaborations and partnerships with research institutions for developing comprehensive genetic panels can also enhance market standing. Industry players should focus on expanding geographically, especially in untapped rural regions with a high thalassemia burden. The beta thalassemia testing market presents a moderately competitive landscape, primarily driven by technological advancements and increasing healthcare expenditure. Companies that can innovate while ensuring compliance and expanding access to testing will likely capitalize on the sector's credibility and growth potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Beta Thalassemia Testing Market

The Beta Thalassemia Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of beta thalassemia worldwide driving demand for specialized testing methods
    • Rising awareness and government initiatives for early detection and management of beta thalassemia
    • Expansion of healthcare infrastructure in developing regions providing access to beta thalassemia testing
  • Market Restraints
    • High costs of advanced testing technologies associated with advanced diagnostic technologies
  • Market Opportunities
    • Development of cost-effective testing methods enabling widespread adoption of beta thalassemia screening
    • Rising public awareness and government initiatives promoting beta thalassemia testing and management
    • Collaborations between healthcare providers and biotech firms facilitating beta thalassemia test advancements
  • Market Challenges
    • Limited access to specialized healthcare facilities in rural and underdeveloped regions for beta thalassemia testing

Porter's Five Forces: A Strategic Tool for Navigating the Beta Thalassemia Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Beta Thalassemia Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Beta Thalassemia Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Beta Thalassemia Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Beta Thalassemia Testing Market

A detailed market share analysis in the Beta Thalassemia Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Beta Thalassemia Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Beta Thalassemia Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Beta Thalassemia Testing Market

A strategic analysis of the Beta Thalassemia Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Beta Thalassemia Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, Asuragen, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., bioMerieux SA, Cepheid, F. Hoffmann-La Roche Ltd., GenMark Diagnostics, Illumina, Inc., Immucor, Inc., Luminex Corporation, PerkinElmer, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Trinity Biotech.

Market Segmentation & Coverage

This research report categorizes the Beta Thalassemia Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Carrier Screening, Diagnostic Testing, Newborn Screening, and Prenatal Testing. The Diagnostic Testing is further studied across Genetic Testing and Hematological Testing. The Prenatal Testing is further studied across Invasive Prenatal Testing and Non-Invasive Prenatal Testing (NIPT).
  • Based on End User, market is studied across Diagnostic Laboratories, Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Technology, market is studied across Microarray Technology, Next-Generation Sequencing (NGS), and PCR (Polymerase Chain Reaction).
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of beta thalassemia worldwide driving demand for specialized testing methods
      • 5.1.1.2. Rising awareness and government initiatives for early detection and management of beta thalassemia
      • 5.1.1.3. Expansion of healthcare infrastructure in developing regions providing access to beta thalassemia testing
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of advanced testing technologies associated with advanced diagnostic technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of cost-effective testing methods enabling widespread adoption of beta thalassemia screening
      • 5.1.3.2. Rising public awareness and government initiatives promoting beta thalassemia testing and management
      • 5.1.3.3. Collaborations between healthcare providers and biotech firms facilitating beta thalassemia test advancements
    • 5.1.4. Challenges
      • 5.1.4.1. Limited access to specialized healthcare facilities in rural and underdeveloped regions for beta thalassemia testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Beta Thalassemia Testing Market, by Test Type

  • 6.1. Introduction
  • 6.2. Carrier Screening
  • 6.3. Diagnostic Testing
    • 6.3.1. Genetic Testing
    • 6.3.2. Hematological Testing
  • 6.4. Newborn Screening
  • 6.5. Prenatal Testing
    • 6.5.1. Invasive Prenatal Testing
    • 6.5.2. Non-Invasive Prenatal Testing (NIPT)

7. Beta Thalassemia Testing Market, by End User

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Hospitals
  • 7.4. Research Institutes
  • 7.5. Specialty Clinics

8. Beta Thalassemia Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. Microarray Technology
  • 8.3. Next-Generation Sequencing (NGS)
  • 8.4. PCR (Polymerase Chain Reaction)

9. Americas Beta Thalassemia Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Beta Thalassemia Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Beta Thalassemia Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. ARUP Laboratories
  • 4. Asuragen, Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Biocept, Inc.
  • 7. bioMerieux SA
  • 8. Cepheid
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. GenMark Diagnostics
  • 11. Illumina, Inc.
  • 12. Immucor, Inc.
  • 13. Luminex Corporation
  • 14. PerkinElmer, Inc.
  • 15. QIAGEN N.V.
  • 16. Quest Diagnostics Incorporated
  • 17. Siemens Healthineers AG
  • 18. Sysmex Corporation
  • 19. Thermo Fisher Scientific Inc.
  • 20. Trinity Biotech

LIST OF FIGURES

  • FIGURE 1. BETA THALASSEMIA TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. BETA THALASSEMIA TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BETA THALASSEMIA TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BETA THALASSEMIA TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BETA THALASSEMIA TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BETA THALASSEMIA TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HEMATOLOGICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING (NIPT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. BETA THALASSEMIA TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. BETA THALASSEMIA TESTING MARKET, FPNV POSITIONING MATRIX, 2023